rs146802593
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PP3_ModeratePP5_Very_Strong
The NM_016180.5(SLC45A2):āc.606G>Cā(p.Trp202Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000185 in 1,613,906 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.00016 ( 0 hom., cov: 32)
Exomes š: 0.00019 ( 0 hom. )
Consequence
SLC45A2
NM_016180.5 missense
NM_016180.5 missense
Scores
13
5
1
Clinical Significance
Conservation
PhyloP100: 7.13
Genes affected
SLC45A2 (HGNC:16472): (solute carrier family 45 member 2) This gene encodes a transporter protein that mediates melanin synthesis. The protein is expressed in a high percentage of melanoma cell lines. Mutations in this gene are a cause of oculocutaneous albinism type 4, and polymorphisms in this gene are associated with variations in skin and hair color. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM1
In a transmembrane_region Helical; Name=5 (size 20) in uniprot entity S45A2_HUMAN there are 6 pathogenic changes around while only 0 benign (100%) in NM_016180.5
PP3
MetaRNN computational evidence supports a deleterious effect, 0.851
PP5
Variant 5-33963973-C-G is Pathogenic according to our data. Variant chr5-33963973-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 521031.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-33963973-C-G is described in Lovd as [Pathogenic]. Variant chr5-33963973-C-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC45A2 | NM_016180.5 | c.606G>C | p.Trp202Cys | missense_variant | 3/7 | ENST00000296589.9 | NP_057264.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC45A2 | ENST00000296589.9 | c.606G>C | p.Trp202Cys | missense_variant | 3/7 | 1 | NM_016180.5 | ENSP00000296589 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152138Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
24
AN:
152138
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000235 AC: 59AN: 251264Hom.: 0 AF XY: 0.000191 AC XY: 26AN XY: 135808
GnomAD3 exomes
AF:
AC:
59
AN:
251264
Hom.:
AF XY:
AC XY:
26
AN XY:
135808
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000187 AC: 274AN: 1461768Hom.: 0 Cov.: 34 AF XY: 0.000155 AC XY: 113AN XY: 727178
GnomAD4 exome
AF:
AC:
274
AN:
1461768
Hom.:
Cov.:
34
AF XY:
AC XY:
113
AN XY:
727178
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000158 AC: 24AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74330
GnomAD4 genome
AF:
AC:
24
AN:
152138
Hom.:
Cov.:
32
AF XY:
AC XY:
18
AN XY:
74330
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
4
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
3
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
24
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 07, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces tryptophan, which is neutral and slightly polar, with cysteine, which is neutral and slightly polar, at codon 202 of the SLC45A2 protein (p.Trp202Cys). This variant is present in population databases (rs146802593, gnomAD 0.2%). This missense change has been observed in individual(s) with oculocutaneous albinism (PMID: 24096233, 27734839). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 521031). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC45A2 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Oculocutaneous albinism type 4 Pathogenic:2
Pathogenic, criteria provided, single submitter | research | Pele Pequeno Principe Research Institute, Faculdades Pequeno Principe | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | May 03, 2018 | The SLC45A2 c.606G>C p.(Trp202Cys) missense variant has been reported in at least two studies in which it is found in a total of five probands including four in a compound heterozygous state, and one in a heterozygous state (Rundshagen et al. 2004; Mauri et al. 2017). The highest frequency of this allele in the Genome Aggregation Database is 0.001712 in the European (Finnish) population (version 2.1.1). Based on the available evidence the c.606G>C p.(Trp202Cys) variant is classified as likely pathogenic for oculocutaneous albinism. - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 30, 2016 | - - |
SLC45A2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 29, 2024 | The SLC45A2 c.606G>C variant is predicted to result in the amino acid substitution p.Trp202Cys. This variant has been reported in individuals with oculocutaneous albinism (Rundshagen et al. 2004. PubMed ID: 14722913; Mauri et al. 2013. PubMed ID: 24096233; Marti et al. 2017. PubMed ID: 28976636). This variant is reported in 0.17% of alleles in individuals of European (Finnish) descent in gnomAD. This variant has been classified as pathogenic or likely pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/521031/). Given the evidence, we interpret this variant as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;M;.
MutationTaster
Benign
D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D
Sift4G
Uncertain
D;D;D
Polyphen
D;D;.
Vest4
MutPred
Gain of catalytic residue at H204 (P = 0.0882);Gain of catalytic residue at H204 (P = 0.0882);.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at